<DOC>
	<DOCNO>NCT02063334</DOCNO>
	<brief_summary>The purpose study investigate whether high-dose vitamin D3 oral bolus ( 2000 microgram ) produce marked vitamin D receptor target gene expression response whether large inter-individual variation .</brief_summary>
	<brief_title>The Effect High-dose Oral Vitamin D3 Bolus Serum 25 ( OH ) D3 Vitamin D Receptor Target Gene Expression</brief_title>
	<detailed_description>Serum 25-hydroxyvitamin D [ 25 ( OH ) D3 ] well-established marker vitamin D status human body . In addition general importance vitamin D bone health , low serum 25 ( OH ) D3 concentration associate increase risk several health outcome , autoimmune disease , type 2 diabetes cardiovascular complication . However , significant inter-individual variation average serum 25 ( OH ) D3 concentration also response supplementation vitamin D. Genetic epigenetic factor suggest responsible large part variation , currently little information health effect variation . In previous study ( VitDmet , Clinicaltrials.gov NCT01479933 ) show half participant respond 5-month vitamin D3 supplementation 40 µg/day 80 µg/day expect certain vitamin D receptor ( VDR ) target gene suitable biomarkers display transcriptomic response human tissue vitamin D3 supplementation . The purpose current study investigate whether high-dose vitamin D3 oral bolus produce mark VDR target gene expression response whether large inter-individual variation , suggest 5-month lower-dose supplementation . In Trial 1 , subject randomize receive either 2,000 microgram ( 80 000 IU ) vitamin D3 ( n=20 ) placebo ( n=10 ) one day . Blood sample collect peripheral blood mononuclear cell isolation serum 25 ( OH ) D3 measurement baseline 24 h 48 h 30 day first dose . Blood sample also collect immunomarker analysis . In Trial 2 , procedure Trial 1 repeat two subject know low high serum 25 ( OH ) D3 concentration order investigate specifically impact different starting level serum 25 ( OH ) D3 . In February 2015 , new subject recruit enter Trial 1 order increase size study . All new subject receive 2,000 microgram bolus vitamin D3 , new subject placebo arm . June 30 , 2016 . Change protocol : There Trial 2 , instead blood sample obtain Trial 1 six subject use additional analysis . The subject select base response vitamin D supplementation Trial 1 .</detailed_description>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Hydroxycholecalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>Nonsmoking BMI 2025 kg/m2 . History kidney stone , renal failure dialysis , hypercalcemia , hypo hyperparathyroidism , severe liver disease ( cirrhosis ) , sarcoidosis granulomatous disease , active chronic tuberculosis Wegener 's granulomatosis . Continuous use antiinflammatory medicine . Regular use supplement contain vitamin D .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>vitamin D3</keyword>
	<keyword>cholecalciferol</keyword>
	<keyword>calcidiol</keyword>
	<keyword>25-hydroxyvitamin D</keyword>
	<keyword>gene expression</keyword>
	<keyword>vitamin D receptor</keyword>
	<keyword>randomize control trial</keyword>
	<keyword>men</keyword>
	<keyword>adult</keyword>
</DOC>